Penetrium Bioscience Unveils Breakthrough Mechanism Solving 137-Year-Old "Seed & Soil" Paradigm, Opening a New Era for Targeted Cancer Therapy
This image was generated by AI and may not depict real events.
Penetrium Bioscience has unveiled a breakthrough mechanism that normalizes the tumor microenvironment, enhancing cancer therapy efficacy and preventing resistance. The company plans to partner with global pharmaceutical companies to integrate its technology into combination therapy regimens.
Penetrium Bioscience has made a significant breakthrough in cancer therapy by developing a mechanism that normalizes the tumor microenvironment, allowing co-administered therapies to achieve full lethal concentrations at the tumor site. This approach enhances therapeutic efficacy and prevents the emergence of adaptive resistance. Studies conducted by Seoul National University Hospital and KAIST validated the findings, confirming that Penetrium's mechanism is broadly applicable across multiple cancers. The company aims to partner with global pharmaceutical companies to restore and extend the value of targeted therapies constrained by resistance. Penetrium will present its full dataset and global clinical development roadmap at AACR 2026 Annual Meeting in San Diego. The company is focused on developing next-generation therapeutics that address the fundamental biological ecosystems underlying disease.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.